ALN-ANG3 Clinical Trials (2026): 2 Studies for Diabetic Kidney Disease (DKD) & Healthy Volunteers With Hyperlipidemia

Where to Participate: All ALN-ANG3 Trial Sites in the U.S. (51 sites across 15 states)

Every actively recruiting ALN-ANG3trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

ALN-ANG3 clinical trials at a glance: phase × recruitment status

Recruiting ALN-ANG3 clinical trials (1)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

ALN-ANG3 clinical trials by indication

ALN-ANG3 pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

All ALN-ANG3 trials (2)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

ALN-ANG3 clinical trials: frequently asked questions

How many ALN-ANG3 clinical trials are there?

2 ALN-ANG3 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.

Are ALN-ANG3 clinical trials recruiting in 2026?

Yes — 1 ALN-ANG3 trial is actively recruiting in 2026, with 51 U.S. sites across 15 states. See the recruiting trials and the per-state site list further down this page.

What conditions is ALN-ANG3 being studied for?

ALN-ANG3 is being studied for Diabetic Kidney Disease (DKD), Healthy Volunteers With Hyperlipidemia. The trials are grouped by indication on this page.

What phase is ALN-ANG3 in?

ALN-ANG3 clinical trials span 1 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors ALN-ANG3 clinical trials?

The lead sponsor across the most ALN-ANG3 trials is Regeneron Pharmaceuticals. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming ALN-ANG3as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.